{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:30:44Z","timestamp":1794011444418,"version":"4.8.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.trim.2022.101538","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T20:36:28Z","timestamp":1642451788000},"page":"101538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"71","author":[{"given":"Tingting","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengtao","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaiyu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binjie","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renyuxue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangli","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.trim.2022.101538_bb0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/imr.12774","article-title":"Updates on CAR T-cell therapy in B-cell malignancies","volume":"290","author":"Jacoby","year":"2019","journal-title":"Immunol. Rev."},{"issue":"9844","key":"10.1016\/j.trim.2022.101538_bb0010","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet."},{"issue":"12","key":"10.1016\/j.trim.2022.101538_bb0020","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int. J. Biol. Sci."},{"issue":"11","key":"10.1016\/j.trim.2022.101538_bb0025","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/d41573-019-00090-z","article-title":"The global pipeline of cell therapies for cancer","volume":"18","author":"Xin","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.trim.2022.101538_bb0030","doi-asserted-by":"crossref","first-page":"e816","DOI":"10.1016\/S2352-3026(20)30277-5","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis","volume":"7","author":"Anagnostou","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.trim.2022.101538_bb0035","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-Cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front. Immunol."},{"issue":"5\u20136","key":"10.1016\/j.trim.2022.101538_bb0040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.trim.2022.101538_bb0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/ITT.S288546","article-title":"Targeting CD22 for the treatment of B-cell malignancies","volume":"10","author":"Shah","year":"2021","journal-title":"Immunotargets Ther"},{"issue":"1","key":"10.1016\/j.trim.2022.101538_bb0050","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41467-017-00836-6","article-title":"Molecular basis of human CD22 function and therapeutic targeting","volume":"8","author":"Ere\u00f1o-Orbea","year":"2017","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.trim.2022.101538_bb0055","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2567.2007.02752.x","article-title":"CD22: an inhibitory enigma","volume":"123","author":"Walker","year":"2008","journal-title":"Immunology."},{"key":"10.1016\/j.trim.2022.101538_bb0060","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3389\/fimmu.2018.02235","article-title":"CD22: a regulator of innate and adaptive B cell responses and autoimmunity","volume":"9","author":"Clark","year":"2018","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.trim.2022.101538_bb0065","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.trim.2022.101538_bb0070","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.CCR-16-0772","article-title":"Phase I study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with\/without rituximab in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"23","author":"Advani","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.trim.2022.101538_bb0075","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.trim.2022.101538_bb0080","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia."},{"issue":"1","key":"10.1016\/j.trim.2022.101538_bb0085","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.trim.2022.101538_bb0090","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0014-5793(97)01062-4","article-title":"Selection and identification of single domain antibody fragments from camel heavy-chain antibodies","volume":"414","author":"Arbabi Ghahroudi","year":"1997","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.trim.2022.101538_bb0095","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13550-021-00750-5","article-title":"Nanobody: a promising toolkit for molecular imaging and disease therapy","volume":"11","author":"Bao","year":"2021","journal-title":"EJNMMI Res."},{"issue":"1","key":"10.1016\/j.trim.2022.101538_bb0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The therapeutic potential of nanobodies","volume":"34","author":"Jov\u010devska","year":"2020","journal-title":"BioDrugs."},{"issue":"5","key":"10.1016\/j.trim.2022.101538_bb0105","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10529-020-02823-2","article-title":"Nanobody against PDL1","volume":"42","author":"Li","year":"2020","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.trim.2022.101538_bb0110","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jconrel.2020.04.030","article-title":"Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session","volume":"323","author":"Deken","year":"2020","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.trim.2022.101538_bb0115","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12951-020-0571-2","article-title":"Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential","volume":"18","author":"Ma","year":"2020","journal-title":"J. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.trim.2022.101538_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/biom11020238","article-title":"The application of nanobody in CAR-T therapy","volume":"11","author":"Bao","year":"2021","journal-title":"Biomolecules."},{"issue":"7","key":"10.1016\/j.trim.2022.101538_bb0125","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.trim.2022.101538_bb0130","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23621","article-title":"Lessons learned from a highly-active CD22-specific chimeric antigen receptor","volume":"2","author":"Long","year":"2013","journal-title":"Oncoimmunology."},{"issue":"7","key":"10.1016\/j.trim.2022.101538_bb0135","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.trim.2022.101538_bb0140","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00002371-199401000-00006","article-title":"Human immune response to monoclonal antibodies","volume":"15","author":"Khazaeli","year":"1994","journal-title":"J. Immunother. Emphasis Tumor Immunol."},{"issue":"3 Suppl","key":"10.1016\/j.trim.2022.101538_bb0145","first-page":"1055s","article-title":"Human immune response to anti-carcinoembryonic antigen murine monoclonal antibodies","volume":"50","author":"Losman","year":"1990","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.trim.2022.101538_bb0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/mab.2013.0080","article-title":"Antibody humanization methods for development of therapeutic applications","volume":"33","author":"Ahmadzadeh","year":"2014","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"10.1016\/j.trim.2022.101538_bb0155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res."},{"key":"10.1016\/j.trim.2022.101538_bb0160","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"1","key":"10.1016\/j.trim.2022.101538_bb0165","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.trim.2022.101538_bb0170","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12943-018-0814-0","article-title":"Engineering chimeric antigen receptor-T cells for cancer treatment","volume":"17","author":"Ye","year":"2018","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.trim.2022.101538_bb0175","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S1470-2045(19)30823-X","article-title":"CAR T cells: continuation in a revolution of immunotherapy","volume":"21","author":"Singh","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trim.2022.101538_bb0180","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41392-019-0070-9","article-title":"Genetically engineered T cells for cancer immunotherapy","volume":"4","author":"Li","year":"2019","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.trim.2022.101538_bb0185","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.imlet.2006.02.007","article-title":"CD28 and ICOS: similar or separate costimulators of T cells?","volume":"105","author":"van Berkel","year":"2006","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.trim.2022.101538_bb0190","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fimmu.2016.00304","article-title":"ICOS co-stimulation: friend or foe?","volume":"7","author":"Wikenheiser","year":"2016","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.trim.2022.101538_bb0195","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.4049\/jimmunol.181.3.1969","article-title":"ICOS ligation recruits the p50alpha PI3K regulatory subunit to the immunological synapse","volume":"181","author":"Fos","year":"2008","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.trim.2022.101538_bb0200","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1084\/jem.20021305","article-title":"A single amino acid alteration in cytoplasmic domain determines IL-2 promoter activation by ligation of CD28 but not inducible costimulator (ICOS)","volume":"197","author":"Harada","year":"2003","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.trim.2022.101538_bb0205","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11427-016-5024-7","article-title":"Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified anti-MUC1 chimeric antigen receptor transduced T cells","volume":"59","author":"You","year":"2016","journal-title":"Sci. China Life Sci."},{"issue":"6","key":"10.1016\/j.trim.2022.101538_bb0210","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.trim.2022.101538_bb0215","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.trim.2022.101538_bb0220","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.trim.2022.101538_bb0225","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia."},{"issue":"1","key":"10.1016\/j.trim.2022.101538_bb0230","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"issue":"6428","key":"10.1016\/j.trim.2022.101538_bb0235","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature."},{"issue":"6","key":"10.1016\/j.trim.2022.101538_bb0240","first-page":"3183","article-title":"Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms","volume":"46","author":"Epenetos","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.trim.2022.101538_bb0245","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol Ther. Oncolytics"}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422000120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422000120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:01:54Z","timestamp":1760810514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327422000120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":48,"alternative-id":["S0966327422000120"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2022.101538","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2022.101538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101538"}}